Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Nymox Pharmaceutical Corporation (NYMX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4100-0.0250 (-5.75%)
At close: 04:00PM EDT
0.4290 +0.02 (+4.63%)
After hours: 04:46PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4350
Open0.4203
Bid0.4101 x 2200
Ask0.4199 x 2200
Day's Range0.3935 - 0.4600
52 Week Range0.3500 - 2.2700
Volume102,385
Avg. Volume252,329
Market Cap34.766M
Beta (5Y Monthly)1.12
PE Ratio (TTM)N/A
EPS (TTM)-0.1500
Earnings DateMay 15, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.25
  • Benzinga

    Why Nymox Pharma Shares Sinking to 52-Week Low?

    Nymox Pharmaceutical Corporation (NASDAQ: NYMX) has received a Refusal to File (RTF) letter from FDA regarding its marketing application for Fexapotide Triflutate. Nymox's position is that clarifications remain to be resolved at a follow-up meeting and that some significant inconsistencies were involved. In March, the company submitted a Fexapotide Triflutate application for benign prostatic hyperplasia (BPH). The letter referred to a new outstanding issue of longer-term safety data and indicate

  • GlobeNewswire

    NYMOX Receives RTF letter from FDA

    IRVINE, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports today that it has received a Refusal to File (“RTF”) letter from FDA on Friday May 20th at 2:48 pm EST, with regard to the Company's New Drug Application (“NDA”) for Fexapotide Triflutate. Nymox’s position is that clarifications remain to be resolved at a follow-up meeting and that some significant inconsistencies were involved. The letter referred to a new outstanding issue of longer-term sa

  • GlobeNewswire

    Nymox Announces Closing of $6.4 Million Financing

    IRVINE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it has closed its $6.4 million financing announced in its filing of March 22 with institutional and accredited investors consisting of 3,878,789 common shares at a purchase price of $1.65 per share, sold pursuant to a registered direct offering. The Company has also issued to the investors, in a concurrent private placement, unregistered warrants to purch

Advertisement
Advertisement